PROGRAMME OF LIVE SESSIONS: CEST timing

The programme below will take place live. This time schedule corresponds to CEST timing. Click here to adapt the CEST time schedule to your own time zone.

If you want to ask questions during the Panel Discussions and Round Tables or if you want to test your knowledge and vote during Interactive Case presentations and debates, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting

ESH EUROPEAN SCHOOL OF HAEMATOLOGY

5th Translational Research Conference
Multiple Myeloma

October 8-11, 2020

Chairpersons : Kenneth C. Anderson, Maria-Victoria Mateos, Philippe Moreau

Thursday, October 8th, 2020

14:00–14:15 Welcome

SESSION I – Smoldering myeloma
Chair: Maria-Victoria Mateos (Salamanca)

14:15-14:20	Introduction	Maria-Victoria Mateos (Salamanca)
14:20-14:35	Clonal evolution in smoldering myeloma	Madhav V. Dhodapkar (Atlanta)
14:35-14:50	High-risk smoldering myeloma	Irene Ghobrial (Boston)
14:50-15:05	Clinical trials	Maria-Victoria Mateos (Salamanca)
15:05-15:12	**Selected brief oral communication** *Whole-genome sequencing of aberrant plasma cells of MGUS patients reveals insights in which patients will progress to MM*	*Benedith Oben (Hasselt)*
15:12-15:40	*Panel discussion*	
15:40-15:50	***Coffee Break***	

SESSION II – Diagnosis of multiple myeloma
Chair: Hervé Avet-Loiseau (Toulouse)

15:50-15:55	Introduction	Hervé Avet-Loiseau (Toulouse)
15:55-16:10	Diagnostic criteria and initial workup	Shaji Kumar (Rochester)
16:10-16:25	Genetics and risk assessment	Hervé Avet-Loiseau (Toulouse)
16:25-16:40	Frailty assessment at diagnosis	Alessandra Larocca (Turin)
16:40-17:10	*Panel discussion*	
17:15	**Mentored Poster Walks**	Bruno Paiva (Pamplona), Sonja Zweegman (Amsterdam)*

Friday, October 9th, 2020

13:20-14:20 **SATELLITE SYMPOSIUM**
What have we learnt about the use of cellular therapies in multiple myeloma ?
Speakers : Maria-Victoria Mateos (Salamanca), Deepu Madduri (New York)

This symposium is organised and supported by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA

SESSION III – Frontline therapy in patients not eligible for autologous stem cell transplantation
Chair: Sonja Zweegman (Amsterdam)

14:25-14-30	Introduction	Sonja Zweegman (Amsterdam)
14:30-14:45	Overview phase 3 trials and newly approved treatments in frontline patients not eligible to stem cell transplantation	Xavier Leleu (Poitiers)
14:45-15:00	Fit vs Frail: the European point of view	Sonja Zweegman (Amsterdam)
15:00-15:15	Fit vs frail: The point of view of North America	Hira Mian (Hamilton)
15:15-15:50	*Panel discussion*	
15:50-16:00	***Coffee break***	

SESSION IV – Frontline therapy in patients eligible for autologous stem cell transplantation
Chair: Philippe Moreau (Nantes)

16:00-16:05	Introduction	Philippe Moreau (Nantes)

16:05-16:20	Overview of European trials	Philippe Moreau (Nantes)
16:20-16:35	US point of view on new trials (including explanation of why HSCT is not proposed frontline)	Paul Richardson (Boston)
16:35-16:50	Maintenance strategies post autologous stem cell transplantation for newly diagnosed multiple myeloma	Graham Jackson (Newcastle)
16:50-17:25	*Panel discussion*	

17:30-18:30 3 Simultaneous Meet the Expert sessions

1. Assessments for MRD evaluation — Francesca Gay (Turin), Noemi Puig (Salamanca)
2. Definition and identification of high-risk myeloma — Hervé Avet-Loiseau (Toulouse), Saad Usmani (Charlotte)
3. Immunoprofiling in myeloma — Madhav Dhodapkar (Atlanta), Bruno Paiva (Pamplona)

Saturday, October 10th, 2020

09:30-10:30 **SATELLITE SYMPOSIUM:**
CAR T cell therapy: A new strategy in relapsed/refractory multiple myeloma
Chair: Maria-Victoria Mateos (Salamanca)
Speakers: Michel Delforge (Leuven), Xavier Leleu (Poitiers), Maria-Victoria Mateos (Salamanca)

This symposium is organized and funded by Bristol Myers Squibb

SESSION V – MRD and the microenvironment
Chair: Elena Zamagni (Bologna)

10:35-10:40	Introduction	Elena Zamagni (Bologna)
10:40-10:55	MRD and imaging	Elena Zamagni (Bologna)
10:55-11:10	MRD and immune profiling (differences in terms of response)	Bruno Paiva (Pamplona)
11:10-11:25	How MRD assessment will impact clinical management	Noemi Puig (Salamanca)
11:25-11:32	**Selected brief oral communication** *Clonally expanded T Cells in multiple myeloma bone marrow show effector differentiation and rarely recognize disease-associated antigens*	*Carlotta Welters (Berlin)*
11:32-12:00	*Panel discussion*	

12:00-13:40 Lunch

12:30-13:30 **SATELLITE SYMPOSIUM:**
Multiple Myeloma: Toward the Implementation of Measurable Residual Disease (MRD) in Clinical Practice
Speakers: Maria-Victoria Mateos (Salamanca), Jeffrey Wolf (San Francisco)

This symposium is organised and funded by Adaptive Biotechnologies

SESSION VI – Relapsed multiple myeloma
Chair: Kenneth C. Anderson (Boston)

13:40-13:45	Introduction	Kenneth C. Anderson (Boston)
13:45-14:00	How to sequence in 1st and 2nd relapse?	Meletios Dimopoulos (Athens)
14:00-14:15	Beyond 2nd relapse	Saad Usmani (Charlotte)
14:15-14:30	Overview immune therapies?	Noopur Raje (Boston)
14:30-14:37	**Selected brief oral communication** *Update of CARTITUDE-1: A phase 1b/2 study of JNJ-68284528 (JNJ-4528), a B-Cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) Cell therapy, in relapsed/refractory multiple myeloma (MM)*	*Deepu Madduri (New York)*
14:37-15:05	*Panel discussion*	

SESSION VII – The future: recent clinical trials in relapse
Chair: Hermann Einsele (Würzburg)

15:05-15:10	Introduction	Hermann Einsele (Würzburg)
15:10-15:25	Novel targeted therapies (not immune)	Shaji Kumar (Rochester)
15:25-15:40	Novel immunotherapies (part 1)	Hermann Einsele (Würzburg)
15:40-15:55	Novel immunotherapies (part 2)	Sagar Lonial (Atlanta)
15:55-16:02	**Selected brief oral communication** *Dreamm-2: single-agent belantamab Mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics*	*Adam D Cohen (Philadelphia)*
16:02-16:25	*Panel discussion*	

16:25-16:35 ***Coffee break***

16:35-17:35 **4 Simultaneous Breakfast Meet the Expert**

1. Management of MM patients Len-refractory — Philippe Moreau (Nantes), Saad Usmani (Charlotte)

2.	How are we going to select the ideal MM patient for CAR-T?	Mohamad Mohty (Paris), Nikhil Munshi (Boston)
3.	Are there new targets in myeloma beyond CD38?	Kenneth C. Anderson (Boston), Paul Richardson (Boston)
4.	Therapeutic strategies targeting the tumor microenvironment	Irene Ghobrial (Boston)

Sunday, October 11th, 2020

10:15-11:15 **SATELLITE SYMPOSIUM**

From bench to bedside: a new dawn for agents targeting b-cell maturation antigen (bcma) in relapsed/refractory multiple myeloma

Speakers: Francesca Gay (Turin), Philippe Moreau (Nantes), Paula Rodriguez (Pamplona), Katja Weisel (Hamburg)

This symposium is organised and funded by GSK

SESSION VIII – Data management issues
Chair: Mohamad Mohty (Paris)

11:20-11:25	Introduction	Mohamad Mohty (Paris)
11:25-11:40	Access to innovative drugs: pharma-academia cooperation	Mohamad Mohty (Paris)
11:40-11:55	iStopMM-a nationwide screening for MGUS and myeloma and early treatment of smoldering myeloma	Sigurdur Kristinsson (Reykjavik)
11:55-12:10	Bureaucracy is strangling clinical research	Steven Le Gouill (Nantes)
12:10-12:40	*Panel discussion*	
12:40-13:30	***Lunch***	

SESSION IX – Plasma cell disorders
Chair: Bertrand Arnulf (Paris)

13:30-13:35	Introduction	Bertrand Arnulf (Paris)
13:35-13:50	Waldenstrom's disease	Jorge Castillo (Boston)
13:50-14:05	POEMS	Arnaud Jaccard (Limoges)
14:05-14:20	Monoclonal gammopathy of clinical significance	Bertrand Arnulf (Paris)
14:20-14:35	Amyloidosis	Giampaolo Merlini (Pavia)
14:35-15:05	*Panel discussion*	

MEETING CLOSURE

**Pending confirmation*